Drug intelligence / Profile preview

LND101

Development stage: Phase 2
Lead developer: Lawson Health Research Institute
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

LND101 is an advanced fecal microbiota transplant (FMT) capsule developed and produced by the Lawson Research Institute. [1, 3] It is a biologic therapy comprised of processed healthy donor fecal material, which contains healthy gut bacteria. [3, 7] Administered orally, LND101 is designed to restore a patient's gut microbiome. [3, 8] It is being studied in clinical trials to treat various cancers, including melanoma, pancreatic cancer, lung cancer, and renal cell carcinoma. [2] The primary goal is to modulate the gut and tumor microbiome to improve the efficacy of immunotherapies and chemotherapies, while also reducing their toxic side effects. [4, 6] Clinical studies have suggested that LND101 can improve response rates to immunotherapy in patients with melanoma and lung cancer and may help eliminate toxic side effects of treatments for kidney cancer. [3, 5]

Other names: fecal microbiota transplant capsule

Beyond the preview

Go deeper on LND101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LND101.

Explore the full profile